Version history

{
  "session_id": "sess_SDA-2026-04-06-gap-pubmed-20260406-062118-5e49e14f_task_9aae8fc5",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "scidex.core.llm.complete",
  "action": "synthesize",
  "content": "```json\n{\n  \"ranked_hypotheses\": [\n    {\n      \"title\": \"PDGF-BB/PDGFRβ/STAT3 Paracrine Signaling Axis Mediates Aβ-Induced SPP1 Upregulation\",\n      \"description\": \"Aβ-activated PDGFRβ+ pericytes secrete PDGF-BB, acting on nearby macrophages via PDGFRβ to induce STAT3-dependent SPP1 expression in a paracrine manner. This creates a cross-talk circuit between pericytes and macrophages amplifying SPP1 production from both cell types.\",\n      \"target_gene\": \"SPP1\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.58,\n        \"novelty\": 0.72,\n        \"feasibility\": 0.65,\n        \"therapeutic_potential\": 0.70,\n        \"mechanistic_plausibility\": 0.63,\n        \"druggability\": 0.62,\n        \"safety_profile\": 0.45,\n        \"competitive_landscape\": 0.68,\n        \"data_availability\": 0.55,\n        \"reproducibility\": 0.60\n      },\n      \"composite_score\": 0.618,\n      \"evidence_for\": [\n        {\"claim\": \"PDGF-BB signaling regulates pericyte function in neurodegeneration\", \"pmid\": \"30755630\"},\n        {\"claim\": \"STAT3 activation by PDGFRβ documented in mesenchymal cells\", \"pmid\": \"31519902\"},\n        {\"claim\": \"Both PDGFRβ+ cells and macrophages express SPP1 in response to Aβ\", \"pmid\": \"36747024\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"PDGFRβ is essential for pericyte recruitment and vessel stability; inhibition risks BBB disruption\", \"pmid\": \"30755630\"},\n        {\"claim\": \"No direct evidence PDGF-BB secretion follows Aβ exposure in pericytes\", \"pmid\": \"36747024\"}\n      ]\n    },\n    {\n      \"title\": \"LRP1/NLRP3/IL-1β Cascade Links Aβ Endocytosis to Inflammasome Activation and SPP1 Induction\",\n      \"description\": \"Perivascular fibroblasts and macrophages clear Aβ oligomers via LRP1, leading to NLRP3 inflammasome activation and IL-1β-dependent SPP1 induction through IL-1R1/MyD88/MAPK signaling.\",\n      \"target_gene\": \"SPP1\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.52,\n        \"novelty\": 0.65,\n        \"feasibility\": 0.70,\n        \"therapeutic_potential\": 0.75,\n        \"mechanistic_plausibility\": 0.55,\n        \"druggability\": 0.72,\n        \"safety_profile\": 0.50,\n        \"competitive_landscape\": 0.70,\n        \"data_availability\": 0.60,\n        \"reproducibility\": 0.58\n      },\n      \"composite_score\": 0.617,\n      \"evidence_for\": [\n        {\"claim\": \"LRP1 mediates Aβ clearance across blood-brain barrier\", \"pmid\": \"28467792\"},\n        {\"claim\": \"NLRP3 inflammasome links Aβ to microglial responses\", \"pmid\": \"29432182\"},\n        {\"claim\": \"IL-1β antagonists approved for clinical use with established safety profiles\", \"pmid\": \"N/A\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"NLRP3 inflammasome typically activated by fibrillar Aβ, not oligomers\", \"pmid\": \"29432182\"},\n        {\"claim\": \"IL-1β blockade shows mixed results in AD models\", \"pmid\": \"N/A\"},\n        {\"claim\": \"NLRP3 inhibitors (MCC950) failed due to liver toxicity\", \"pmid\": \"N/A\"}\n      ]\n    },\n    {\n      \"title\": \"CD36 Acts as Primary Aβ Oligomer Sensor on Perivascular Macrophages, Triggering NF-κB-Dependent SPP1 Transcription\",\n      \"description\": \"CD36 scavenger receptor binds Aβ42 oligomers, forming a signaling complex with TLR4/TLR6 that activates downstream NF-κB and AP-1 transcription factors, directly driving SPP1 promoter activation.\",\n      \"target_gene\": \"SPP1\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.55,\n        \"novelty\": 0.58,\n        \"feasibility\": 0.50,\n        \"therapeutic_potential\": 0.52,\n        \"mechanistic_plausibility\": 0.50,\n        \"druggability\": 0.35,\n        \"safety_profile\": 0.55,\n        \"competitive_landscape\": 0.60,\n        \"data_availability\": 0.65,\n        \"reproducibility\": 0.52\n      },\n      \"composite_score\": 0.532,\n      \"evidence_for\": [\n        {\"claim\": \"CD36 mediates microglial inflammatory responses to Aβ\", \"pmid\": \"30918303\"},\n        {\"claim\": \"CD36-TLR4 heterodimers sense Aβ fibrils\", \"pmid\": \"31853058\"},\n        {\"claim\": \"Perivascular macrophages are primary source of Aβ-induced SPP1\", \"pmid\": \"36747024\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"CD36 may preferentially bind Aβ fibrils rather than oligomers\", \"pmid\": \"26341295\"},\n        {\"claim\": \"CD36 knockout mice show variable phenotypic penetrance\", \"pmid\": \"29705649\"},\n        {\"claim\": \"NF-κB activates hundreds of genes; specificity for SPP1 unexplained\", \"pmid\": \"N/A\"}\n      ]\n    },\n    {\n      \"title\": \"YAP/TAZ Mechanosensing Cooperates with NF-κB to Amplify SPP1 Transcription in Perivascular Fibroblasts\",\n      \"description\": \"Aβ oligomers induce cytoskeletal remodeling and nuclear translocation of YAP/TAZ, which synergize with NF-κB to drive robust SPP1 expression in perivascular fibroblasts experiencing unique mechanical cues.\",\n      \"target_gene\": \"SPP1\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.42,\n        \"novelty\": 0.80,\n        \"feasibility\": 0.40,\n        \"therapeutic_potential\": 0.48,\n        \"mechanistic_plausibility\": 0.42,\n        \"druggability\": 0.30,\n        \"safety_profile\": 0.60,\n        \"competitive_landscape\": 0.75,\n        \"data_availability\": 0.35,\n        \"reproducibility\": 0.40\n      },\n      \"composite_score\": 0.492,\n      \"evidence_for\": [\n        {\"claim\": \"YAP/TAZ mediate mechanotransduction in fibrosis contexts\", \"pmid\": \"29358690\"},\n        {\"claim\": \"YAP/TAZ activation documented in Aβ-challenged cells\", \"pmid\": \"33408396\"},\n        {\"claim\": \"Fibroblasts show significant SPP1 upregulation in Aβ environments\", \"pmid\": \"36747024\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"Direct YAP/TAZ binding to SPP1 promoter not established\", \"pmid\": \"33408396\"},\n        {\"claim\": \"Aβ oligomers in solution may not provide mechanical stress signal\", \"pmid\": \"N/A\"},\n        {\"claim\": \"Mechanosensing pathways highly context-dependent; in vitro may not translate\", \"pmid\": \"N/A\"}\n      ]\n    },\n    {\n      \"title\": \"TREM2 on Perivascular Macrophages Senses Aβ and Drives SPP1 Upregulation Through CSF1R-Mediated Survival and Metabolic Signaling\",\n      \"description\": \"TREM2 recognizes Aβ oligomers and phosphatidylserine, activating SYK kinase and sustaining CSF1R expression. This drives metabolic reprogramming toward glycolysis via HIF1α stabilization, creating a permissive environment for SPP1 expression.\",\n      \"target_gene\": \"SPP1\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.48,\n        \"novelty\": 0.55,\n        \"feasibility\": 0.45,\n        \"therapeutic_potential\": 0.60,\n        \"mechanistic_plausibility\": 0.42,\n        \"druggability\": 0.48,\n        \"safety_profile\": 0.52,\n        \"competitive_landscape\": 0.58,\n        \"data_availability\": 0.50,\n        \"reproducibility\": 0.48\n      },\n      \"composite_score\": 0.496,\n      \"evidence_for\": [\n        {\"claim\": \"TREM2 regulates macrophage metabolic state in AD\", \"pmid\": \"34625536\"},\n        {\"claim\": \"Perivascular macrophages express TREM2; variants affect Aβ responses\", \"pmid\": \"36747024\"},\n        {\"claim\": \"TREM2 deficiency alters macrophage function around plaques\", \"pmid\": \"29358688\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"TREM2 has no confirmed direct affinity for Aβ oligomers\", \"pmid\": \"34625536\"},\n        {\"claim\": \"TREM2 loss-of-function variants increase AD risk; compensatory pathways likely\", \"pmid\": \"N/A\"},\n        {\"claim\": \"HIF1α is general stress response; specific SPP1 targeting undemonstrated\", \"pmid\": \"N/A\"}\n      ]\n    },\n    {\n      \"title\": \"RAGE/STAT3/IL-6 Autocrine Loop Mediates Aβ-Induced SPP1 Upregulation in Perivascular Fibroblasts\",\n      \"description\": \"RAGE on perivascular fibroblasts binds Aβ42 oligomers, activating NADPH oxidase and ROS production. This triggers STAT3 phosphorylation through JAK/IL-6 signaling, creating an autocrine amplification loop driving SPP1 expression.\",\n      \"target_gene\": \"SPP1\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.40,\n        \"novelty\": 0.52,\n        \"feasibility\": 0.38,\n        \"therapeutic_potential\": 0.45,\n        \"mechanistic_plausibility\": 0.38,\n        \"druggability\": 0.42,\n        \"safety_profile\": 0.50,\n        \"competitive_landscape\": 0.55,\n        \"data_availability\": 0.42,\n        \"reproducibility\": 0.40\n      },\n      \"composite_score\": 0.442,\n      \"evidence_for\": [\n        {\"claim\": \"RAGE mediates Aβ-induced neuroinflammation\", \"pmid\": \"28794332\"},\n        {\"claim\": \"STAT3 directly regulates SPP1 expression in wound healing\", \"pmid\": \"29590635\"},\n        {\"claim\": \"Fibroblasts upregulate SPP1 in response to Aβ oligomers\", \"pmid\": \"36747024\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"RAGE expression on perivascular fibroblasts not documented\", \"pmid\": \"N/A\"},\n        {\"claim\": \"RAGE knockout mice show minimal phenotypes in some AD models\", \"pmid\": \"18784645\"},\n        {\"claim\": \"SPP1 reported as STAT3-repressed in some contexts\", \"pmid\": \"25991012\"}\n      ]\n    },\n    {\n      \"title\": \"P2X7/P2Y12 Purinergic Signaling Connects Aβ Aggregation to SPP1 Transcription via Calcineurin/NFAT Pathway\",\n      \"description\": \"Aβ oligomer binding causes local depolarization and ATP release from stressed cells. P2X7 on perivascular cells allows Ca2+ influx, activating calcineurin and NFATc1, which cooperates with AP-1 to drive SPP1 transcription.\",\n      \"target_gene\": \"SPP1\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.38,\n        \"novelty\": 0.62,\n        \"feasibility\": 0.32,\n        \"therapeutic_potential\": 0.40,\n        \"mechanistic_plausibility\": 0.35,\n        \"druggability\": 0.48,\n        \"safety_profile\": 0.45,\n        \"competitive_landscape\": 0.65,\n        \"data_availability\": 0.38,\n        \"reproducibility\": 0.38\n      },\n      \"composite_score\": 0.423,\n      \"evidence_for\": [\n        {\"claim\": \"P2X7 activation by extracellular ATP promotes neuroinflammation in AD\", \"pmid\": \"31069268\"},\n        {\"claim\": \"Calcineurin/NFAT regulates SPP1 in inflammatory macrophages\", \"pmid\": \"31439799\"},\n        {\"claim\": \"SPP1 upregulation occurs in Aβ-rich environments\", \"pmid\": \"36747024\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"Critical link (Aβ → ATP release) not demonstrated in perivascular cells\", \"pmid\": \"N/A\"},\n        {\"claim\": \"P2X7 typically requires mM ATP during cell lysis, not subtle stress\", \"pmid\": \"N/A\"},\n        {\"claim\": \"Multiple speculative intermediaries reduce mechanistic clarity\", \"pmid\": \"N/A\"}\n      ]\n    }\n  ],\n  \"knowledge_edges\": [\n    {\"source_id\": \"PDGF-BB/PDGFRβ/STAT3\", \"source_type\": \"hypothesis\", \"target_id\": \"PDGFRβ\", \"target_type\": \"receptor\", \"relation\": \"initiates\"},\n    {\"source_id\": \"PDGF-BB/PDGFRβ/STAT3\", \"source_type\": \"hypothesis\", \"target_id\": \"STAT3\", \"target_type\": \"transcription_factor\", \"relation\": \"activates\"},\n    {\"source_id\": \"PDGF-BB/PDGFRβ/STAT3\", \"source_type\": \"hypothesis\", \"target_id\": \"SPP1\", \"target_type\": \"gene\", \"relation\": \"upregulates\"},\n    {\"source_id\": \"LRP1/NLRP3/IL-1β\", \"source_type\": \"hypothesis\", \"target_id\": \"LRP1\", \"target_type\": \"receptor\", \"relation\": \"mediates_endocytosis\"},\n    {\"source_id\": \"LRP1/NLRP3/IL-1β\", \"source_type\": \"hypothesis\", \"target_id\": \"NLRP3\", \"target_type\": \"inflammasome\", \"relation\": \"activates\"},\n    {\"source_id\": \"LRP1/NLRP3/IL-1β\", \"source_type\": \"hypothesis\", \"target_id\": \"IL1B\", \"target_type\": \"cytokine\", \"relation\": \"produces\"},\n    {\"source_id\": \"LRP1/NLRP3/IL-1β\", \"source_type\": \"hypothesis\", \"target_id\": \"SPP1\", \"target_type\": \"gene\", \"relation\": \"upregulates\"},\n    {\"source_id\": \"CD36/NF-κB\", \"source_type\": \"hypothesis\", \"target_id\": \"CD36\", \"target_type\": \"receptor\", \"relation\": \"senses_Aβ\"},\n    {\"source_id\": \"CD36/NF-κB\", \"source_type\": \"hypothesis\", \"target_id\": \"NFKB1\", \"target_type\": \"transcription_factor\", \"relation\": \"activates\"},\n    {\"source_id\": \"CD36/NF-κB\", \"source_type\": \"hypothesis\", \"target_id\": \"SPP1\", \"target_type\": \"gene\", \"relation\": \"upregulates\"},\n    {\"source_id\": \"TREM2/CSF1R/HIF1α\", \"source_type\": \"hypothesis\", \"target_id\": \"TREM2\", \"target_type\": \"receptor\", \"relation\": \"senses_Aβ\"},\n    {\"source_id\": \"TREM2/CSF1R/HIF1α\", \"source_type\": \"hypothesis\", \"target_id\": \"CSF1R\", \"target_type\": \"receptor\", \"relation\": \"sustains\"},\n    {\"source_id\": \"TREM2/CSF1R/HIF1α\", \"source_type\": \"hypothesis\", \"target_id\": \"HIF1A\", \"target_type\": \"transcription_factor\", \"relation\": \"stabilizes\"},\n    {\"source_id\": \"RAGE/STAT3/IL-6\", \"source_type\": \"hypothesis\", \"target_id\": \"RAGE\", \"target_type\": \"receptor\", \"relation\": \"senses_Aβ\"},\n    {\"source_id\": \"RAGE/STAT3/IL-6\", \"source_type\": \"hypothesis\", \"target_id\": \"STAT3\", \"target_type\": \"transcription_factor\", \"relation\": \"activates\"},\n    {\"source_id\": \"RAGE/STAT3/IL-6\", \"source_type\": \"hypothesis\", \"target_id\": \"IL6\", \"target_type\": \"cytokine\", \"relation\": \"amplifies\"},\n    {\"source_id\": \"P2X7/Calcineurin/NFAT\", \"source_type\": \"hypothesis\", \"target_id\": \"P2RX7\", \"target_type\": \"receptor\", \"relation\": \"senses_ATP\"},\n    {\"source_id\": \"P2X7/Calcineurin/NFAT\", \"source_type\": \"hypothesis\", \"target_id\": \"PPP3CA\", \"target_type\": \"phosphatase\", \"relation\": \"activates\"},\n    {\"source_id\": \"P2X7/Calcineurin/NFAT\", \"source_type\": \"hypothesis\", \"target_id\": \"NFATC1\", \"target_type\": \"transcription_factor\", \"relation\": \"dephosphorylates\"},\n    {\"source_id\": \"YAP/TAZ mechanosensing\", \"source_type\": \"hypothesis\", \"target_id\": \"YAP1\", \"target_type\": \"transcription_factor\", \"relation\": \"translocates_nucleus\"},\n    {\"source_id\": \"YAP/TAZ mechanosensing\", \"source_type\": \"hypothesis\", \"target_id\": \"WWTR1\", \"target_type\": \"transcription_factor\", \"relation\": \"translocates_nucleus\"},\n    {\"source_id\": \"cross_pathway\", \"source_type\": \"transcription_factor\", \"target_id\": \"SPP1\", \"target_type\": \"gene\", \"relation\": \"convergent_target\"},\n    {\"source_id\": \"SPP1\", \"source_type\": \"gene\", \"target_id\": \"microglial_phagocytic_states\", \"target_type\": \"phenotype\", \"relation\": \"induces\"},\n    {\"source_id\": \"SPP1\", \"source_type\": \"gene\", \"target_id\": \"synaptic_engulfment\", \"target_type\": \"phenotype\", \"relation\": \"enhances\"}\n  ],\n  \"synthesis_summary\": \"Analysis of seven mechanistic hypotheses for Aβ-induced SPP1 upregulation in perivascular cells reveals two frontrunners with distinct therapeutic profiles. The PDGF-BB/PDGFRβ/STAT3 paracrine axis (composite score 0.618) emerges as the highest-priority hypothesis due to its tractable therapeutic angle—existing PDGFR inhibitors (imatinib, sunitinib) could be repurposed—though safety concerns about vascular integrity require careful dose optimization. The LRP1/NLRP3/IL-1β cascade (0.617) offers the most clinically mature development path, leveraging FDA-approved IL-1β antagonists (anakinra, canakinumab) despite CNS penetration limitations. The critical scientific gap across all hypotheses is tissue-specific validation: perivascular macrophage and fibroblast receptor expression patterns remain largely uncharacterized, and the direct mechanistic link to SPP1 transcription lacks ChIP-seq confirmation for any proposed pathway. A convergent therapeutic strategy targeting STAT3 or IL-1β downstream of multiple upstream sensors may provide broader benefit than single-receptor antagonism, but requires fundamental validation of perivascular cell-specific signaling before rational drug design can proceed.\"\n}",
  "tokens_used": "3808",
  "persona_id": "persona-synthesizer"
}